

PROTECTIX 400 MG/2000 MG SPOT-ON SOLUTION FOR DOGS OVER 25 KG UP TO 40 KG

Authorised

- Imidacloprid
- Permethrin

Product identification

Medicine name:

PROTECTIX 400 MG/2000 MG SPOT-ON SOLUTION FOR DOGS OVER 25 KG UP TO 40 KG

ProtecTix 400 mg/2000 mg διάλυμα για επίχυση σε σημείο για σκύλους άνω των 25 kg έως 40 kg

Active substance:

Imidacloprid

Permethrin

Target species:

Dog

Route of administration:

Cutaneous use

Product details

Active substance and strength:

Imidacloprid

400.00 milligram(s) / 1.00 Pipette

Permethrin

2000.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:

Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP53AC54

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Greece

Package description:

Pack containing 1 PET/PE/aluminium/surlyn sachet containing one white polypropylene unit dose pipette

Pack containing 2 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 3 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 4 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 6 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 12 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 24 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Beaphar B.V.

Marketing authorisation date:

20/02/2024

Manufacturing sites for batch release:

Beaphar B.V.

Responsible authority:

National Organization For Medicines

Authorisation number:

20216/21-02-2024/K-0250604

Date of authorisation status change:

20/02/2024

Reference member state:

France

Procedure number:

FR/V/0433/004

Concerned member states:

Croatia Cyprus Czechia Germany Greece Hungary Italy Latvia Lithuania
Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.